Leprosy 2 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

LPRS2 MCID: LPR022 MIFTS: 26	Leprosy 2 (LPRS2) Categories: Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Leprosy 2

MalaCards integrated aliases for Leprosy 2:

Name: Leprosy 2 ⁵⁷

Leprosy, Susceptibility to, 2 ⁵⁷ ²⁸ ⁵ ⁷¹

Leprosy, Type 2 ³⁸

Leprosy ⁷¹

Lprs2 ⁵⁷

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Infectious diseases
Anatomical: Neuronal diseases Reproductive diseases Immune diseases Eye diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 607572

UMLS ⁷¹ C0023343 C1843632

Sources

Summaries for Leprosy 2

MalaCards based summary: Leprosy 2, also known as leprosy, susceptibility to, 2, is related to leprosy 3 and oto-palatal-digital syndrome. An important gene associated with Leprosy 2 is PRKN (Parkin RBR E3 Ubiquitin Protein Ligase). The drugs Levoleucovorin and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and neutrophil.

More information from OMIM: 607572

Sources

Related Diseases for Leprosy 2

Diseases in the Leprosy 3 family:

Leprosy 2	Leprosy 1
Leprosy 4	Leprosy 5
Leprosy 6

Diseases related to Leprosy 2 via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score
1	leprosy 3	10.4
2	oto-palatal-digital syndrome	10.0
3	lepromatous leprosy	9.9
4	autoimmune disease	9.9
5	neutropenia	9.9
6	chromoblastomycosis	9.9
7	mucormycosis	9.9
8	tuberculoid leprosy	9.8

Graphical network of the top 20 diseases related to Leprosy 2:

Sources

Symptoms & Phenotypes for Leprosy 2

Clinical features from OMIM®:

607572 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Leprosy 2

Drugs for Leprosy 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Vitamins

Phase 4

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Folic Acid Antagonists

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Antiprotozoal Agents

Phase 4

Antiparasitic Agents

Phase 4

Vitamin B Complex

Phase 4

Antimalarials

Phase 4

Prednisolone phosphate

Approved, Vet_approved

Phase 2, Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2, Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2, Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2, Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2, Phase 3

83-43-2

4159 6741

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2, Phase 3

23593-75-1

2812

Amitriptyline

Approved

Phase 3

50-48-6

2160

Tramadol

Approved, Investigational

Phase 3

27203-92-5

33741 5523

Bedaquiline

Approved

Phase 3

843663-66-1

5388906

Prednisolone hemisuccinate

Experimental

Phase 2, Phase 3

2920-86-7

4897

Immunosuppressive Agents

Phase 2, Phase 3

Hormones

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

Antirheumatic Agents

Phase 2, Phase 3

Antineoplastic Agents, Hormonal

Phase 2, Phase 3

Calcineurin Inhibitors

Phase 2, Phase 3

Cyclosporins

Phase 2, Phase 3

Antifungal Agents

Phase 2, Phase 3

glucocorticoids

Phase 2, Phase 3

Methylprednisolone Acetate

Phase 2, Phase 3

584547

Immunologic Factors

Phase 2, Phase 3

Analgesics

Phase 3

Neurotransmitter Agents

Phase 3

Adrenergic Agents

Phase 3

Psychotropic Drugs

Phase 3

Antidepressive Agents, Tricyclic

Phase 3

Antidepressive Agents

Phase 3

Analgesics, Opioid

Phase 3

Analgesics, Non-Narcotic

Phase 3

Narcotics

Phase 3

Antitubercular Agents

Phase 3

Antibiotics, Antitubercular

Phase 3

Immunoglobulin M

Phase 3

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

CC-11050

Investigational

Phase 2

340019-69-4

Interventional clinical trials:

(show all 37)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome	Unknown status	NCT02550080	Phase 4	Dapsone
2	Effect of Additional Clofazimine on ENL Reactions in Leprosy	Completed	NCT01290744	Phase 4	Clofazimine;Placebo
3	Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients	Completed	NCT00669643	Phase 4	PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
4	Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers	Completed	NCT01165840	Phase 4	Dapsone
5	A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions	Completed	NCT00919815	Phase 2, Phase 3	Ciclosporin;Prednisolone
6	Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study	Active, not recruiting	NCT03324035	Phase 3	Amitriptyline;Placebo oral capsule;Tramadol
7	Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar	Active, not recruiting	NCT03662022	Phase 3	Rifampicin
8	Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 Study	Not yet recruiting	NCT05597280	Phase 3	BE-PEP Bedaquiline;SDR-PEP Rifampicin;BE-PEP Rifampicin
9	Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region	Completed	NCT00128193	Phase 2
10	A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only.	Completed	NCT00919776	Phase 2	prednisolone;ciclosporin
11	A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.	Completed	NCT00919542	Phase 2	Ciclosporin;prednisolone
12	A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.	Completed	NCT00919451	Phase 2	ciclosporin
13	Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 2 Study	Recruiting	NCT05406479	Phase 2	BE-PEP (Bedaquiline);SDR-PEP;BE-PEP (Rifampicine)
14	A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum	Recruiting	NCT03807362	Phase 2	CC-11050
15	An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy	Active, not recruiting	NCT03384641	Phase 2	Bedaquiline 200 mg
16	Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia	Not yet recruiting	NCT05243654	Phase 2	Metformin;Placebo
17	A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy	Not yet recruiting	NCT03947437	Phase 1, Phase 2
18	The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study	Withdrawn	NCT01885611	Phase 1, Phase 2
19	Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA	Completed	NCT01920750	Phase 1
20	Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients	Completed	NCT01006759	Phase 1
21	A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects	Completed	NCT03302897	Phase 1
22	Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial	Unknown status	NCT03072004
23	Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy	Unknown status	NCT00406861		montelukast in treatment of ENL reaction
24	Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia	Unknown status	NCT03683745
25	Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis	Completed	NCT02085317		acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
26	Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial	Completed	NCT00860717
27	Improved Understanding of Ongoing Transmission of Leprosy in the Comoros, a Region Hyperendemic for the Disease.	Completed	NCT03526718
28	Molecular Epidemiology of Leprosy in Colombia	Completed	NCT00138437
29	Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting	Completed	NCT02484469
30	Molecular Epidemiology of Leprosy - Philippines	Completed	NCT00315809
31	Modified Tarsorrhaphy vs Gold Weight Implant Technique for Paralytic Lagophthalmos Treatment in Leprosy Patients: a Randomized Clinical Trial	Completed	NCT04944498
32	The Evaluation of Treatment of Leprosy Wounds With Traditional Chinese Herbal Medicine Complex "Jingchuang Ointment"	Recruiting	NCT05047809
33	Epidemiology of Leprosy in French Guiana	Recruiting	NCT05031091
34	A Clinical Study on the Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients in Taiwan	Recruiting	NCT05091216
35	Clofazamine in the Long Term Treatment of Leprosy, Phase III	No longer available	NCT00852345		clofazamine
36	CD8 Reactivity to Microorganisms in Blood and Breast Milk	Terminated	NCT03084614
37	Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer.	Terminated	NCT01751503

Search NIH Clinical Center for Leprosy 2

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Thalidomide

Sources

Genetic Tests for Leprosy 2

Genetic tests related to Leprosy 2:

#	Genetic test	Affiliating Genes
1	Leprosy, Susceptibility to, 2 ²⁸

Sources

Anatomical Context for Leprosy 2

Organs/tissues related to Leprosy 2:

MalaCards : Skin, Breast, Neutrophil

Sources

Publications for Leprosy 2

Articles related to Leprosy 2:

(show top 50) (show all 53)

#	Title	Authors	PMID	Year
1	Linkage disequilibrium pattern and age-at-diagnosis are critical for replicating genetic associations across ethnic groups in leprosy. ⁵⁷	Alter A...Schurr E	23052943	2013
2	Association study of major risk single nucleotide polymorphisms in the common regulatory region of PARK2 and PACRG genes with leprosy in an Indian population. ⁵⁷	Malhotra D...Bamezai RN	16391553	2006
3	Susceptibility to leprosy is associated with PARK2 and PACRG. ⁵⁷	Mira MT...Schurr E	14737177	2004
4	Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. ⁵⁷	Mira MT...Schurr E	12577057	2003
5	A major susceptibility locus for leprosy in India maps to chromosome 10p13. ⁵⁷	Siddiqui MR...Hill AV	11279529	2001
6	Genomic control for association studies. ⁵⁷	Devlin B...Roeder K	11315092	1999
7	Are the neglected tropical diseases under control in the tri-border region between Brazil, Argentina, and Paraguay? ⁶²	Mendes Oliveira F...Fronteira I	35404862	2022
8	A comparison of three types of targeted, community-based methods aimed at promoting early detection of new leprosy cases in rural parts of three endemic states in India. ⁶²	Govindasamy K...Dutta A	34905570	2021
9	Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions. ⁶²	da Silva CO...Pessolani MCV	31504035	2019
10	Study of S100 Immunostaining in Demonstrating Neural Granulomas in Paucibacillary Leprosy. ⁶²	Shenoy N...Nair NG	29937557	2018
11	Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. ⁶²	Schmitz V...Sarno EN	27556927	2016
12	Profile of Rheumatological Manifestations in Leprosy in a Tertiary Care Hospital from Himachal Pradesh. ⁶²	Singh R...Rawat R	29741821	2016
13	Neuropathy in elderly: lessons learnt from nerve biopsy. ⁶²	Anish L...Taly AB	25362502	2015
14	Lucio Leprosy with Lucio's phenomenon, digital gangrene and anticardiolipin antibodies. ⁶²	Nunzie E...Massone C	25509720	2014
15	Clinical use and control of the dispensing of thalidomide in Brasilia-Federal District, Brazil, from 2001 to 2012. ⁶²	Paumgartten FJ...de Souza NR	24196904	2013
16	Delusional infestation: a clinical profile. ⁶²	Bhatia MS...Srivastava S	23466108	2013
17	Patterns of migration and risks associated with leprosy among migrants in Maranhão, Brazil. ⁶²	Murto C...Heukelbach J	24040433	2013
18	Mucormycosis and chromoblastomycosis occurring in a patient with leprosy type 2 reaction under prolonged corticosteroid and thalidomide therapy. ⁶²	Basilio FM...Moritz S	23044573	2012
19	Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy type 2 reaction. ⁶²	Sousa AL...Stefani MM	22459738	2012
20	Azathioprine as a steroid sparing agent in leprosy type 2 reactions: report of nine cases. ⁶²	Duraes SM...Gazzeta MO	22125939	2011
21	[The current challenge of imported leprosy in Spain: a study of 7 cases]. ⁶²	Contreras-Steyls M...Herrera E	21334586	2011
22	[Epidemiological profile of leprosy in a Brazilian municipality between 2000 and 2006]. ⁶²	Miranzi Sde S...Nunes AA	20305971	2010
23	Leprosy. ⁶²	Lockwood DNj	19454067	2007
24	[Late-occurring cutaneous vasculitis after successful treatment of diffuse lepromatous leprosy: Lucio's phenomenon]. ⁶²	Fenniche S...Mokhtar I	17506277	2007
25	Increased prevalence of human T cell lymphotropic virus type 1 in patients attending a Brazilian dermatology clinic. ⁶²	Nobre V...GIPH (HTLV-1/2Research Interdisciplinary Group)	17622792	2007
26	Study of patients presenting with symptoms of peripheral neuropathy and thickened greater auricular nerve. ⁶²	Neopane A...Karki DB	16340253	2003
27	Male-female (sex) differences in leprosy patients in south eastern Nigeria: females present late for diagnosis and treatment and have higher rates of deformity. ⁶²	Peters ES...Eshiet AL	12449892	2002
28	Spectrum of dermatopathologic lesions associated with HIV/AIDS in India. ⁶²	Lanjewar DN...Iyer A	12785169	2002
29	Ocular manifestations of leprosy in a noninstitutionalized community in the United States. ⁶²	Dana MR...Sugar J	8185519	1994
30	Denatured muscle grafts for nerve repair in an experimental model of nerve damage in leprosy. 2. Recovery of peripheral peptide-containing nerves assessed by quantitative immunohistochemical study. ⁶²	Santamaria L...Polak JM	7514642	1994
31	Intracardiac autonomic ganglion cells in leprosy and dilated cardiomyopathy. ⁶²	Ray R...Kaur S	8365740	1993
32	[Cutaneous neoplasms during leprosy: 2 case reports]. ⁶²	Sanlorenzo M...Mounden JC	1293912	1992
33	A study of morbidity pattern among prostitutes attending a municipal clinic in Pune. ⁶²	Urmil AC...Ganguly SS	2789264	1989
34	[Study on prevention of leprosy. 2. Chemo-prophylaxis trial for leprosy household contact children]. ⁶²	Saikawa K	3842969	1985
35	Leprosy. XII. T-cell subsets in lepromatous leprosy. ⁶²	Lim SD...Fusaro RM	6983504	1982
36	Phagocytosis in leprosy. 2. Production of superoxide by circulating blood leukocytes from lepromatous patients. ⁶²	Rojas-Espinosa O	215566	1978
37	Persistence of Australia antigen in leprosy--a frustrating puzzle in immunology. ⁶²	Saoji AM...Mene AR	651319	1978
38	The role of protein malnutrition in the pathogenesis of ulcerative "Lazarine" leprosy. ⁶²	Skinsnes LK...Higa LH	824211	1976
39	The histopathology of lepromatous leprosy in the nose. ⁶²	McDougall AC...Kanan MW	1099180	1975
40	Acid mucopolysaccharide metabolism in leprosy. 2. Subcellular localization of hyaluronic acid and beta-glucuronidase in leprous infiltrates suggestive of a host-Mycobacterium leprae metabolic relationship. ⁶²	Matsuo E...Skinsnes OK	4282081	1974
41	Experimental murine leprosy. 2. Further evidence for varying susceptibility of outbred mice and evaluation of the response of 5 inbred mouse strains to infection with Mycobacterium lepraemurium. ⁶²	Closs O...Haugen OA	4604462	1974
42	Immunologic studies on leprosy. 2. Antigenic studies of Mycobacterium leprae. ⁶²	Navalkar RG	4131110	1973
43	The control and management of leprosy. 2. ⁶²	Sister Gabrielle	4496656	1973
44	Lipids in leprosy. 2. Histochemistry of lipids in human leprosy. ⁶²	Sakurai I...Skinsnes OK	4102020	1970
45	Leprosy. 2. ⁶²	Cheung PL	5434944	1970
46	Nerves in the arm in leprosy. 2. Pathology, pathogenesis and clinical correlations. ⁶²	Dastur DK...Antia NH	4098603	1970
47	[Consideration and discussion of the pathogenesis of leprosy, with special reference to the influence of specific histological changes in the reticuloendothelial system on the progress of and recovery from leprosy. 2]. ⁶²	Harada Y	5686369	1968
48	Studies on sulfone resistance in leprosy. 2. Treatment with a riminophenazine derivative (B.663). ⁶²	Pettit JH...Rees RJ	6006070	1966
49	The facial nerve in leprosy. 2. Pathology, pathogenesis, electromyography and clinical correlations. ⁶²	Dastur DK...Divekar SC	5950064	1966
50	Epidemiology of disability in leprosy. 2. Factors associated with low disability. ⁶²	Srinivasan H...Noordeen SK	5950068	1966